CoChat

Obesity-associated NLRC4 inflammasome activation drives breast cancer progression

Open access

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Obesity is associated with an increased risk of developing breast cancer and is also associated with worse clinical prognosis. The mechanistic link between obesity and breast cancer progression remains unclear, and there has been no development of specific treatments to improve the outcome of obese cancer patients. Here we show that obesity-associated NLRC4 inflammasome activation/ interleukin (IL)-1 signalling promotes breast cancer progression. The tumour microenvironment in the context of obesity induces an increase in tumour-infiltrating myeloid cells with an activated NLRC4 inflammasome that in turn activates IL-1β, which drives disease progression through adipocyte-mediated vascular endothelial growth factor A (VEGFA) expression and angiogenesis. Further studies show that treatment of mice with metformin inhibits obesity-associated tumour progression associated with a marked decrease in angiogenesis. This report provides a causal mechanism by which obesity promotes breast cancer progression and lays out a foundation to block NLRC4 inflammasome activation or IL-1β signalling transduction that may be useful for the treatment of obese cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms13007

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The IL-1β/IL-1R1 axis promotes tumour growth in diet-induced obese mice. The indicated mice were given either a ND or HFD for 10 weeks, and then the indicated cells were implanted into the #4 mammary gland. See Supplementary Fig. 2b. (a–c) Mice were treated with anti-IL-1R1 antibody or control IgG once tumours were palpable (a,c) or with recombinant IL-1 receptor antagonist (rIL1RA) (b) starting the day of Py8119 cell transplant. Data represent the average tumour volume±s.e.m (a–b: n=5 HFD+IgG, n=5 HFD+anti-IL-1R1, n=5 HFD+anti-IL1RA n=14 ND, n=24 HFD; C: n=5 all groups). (d,e) Data represent the average body weight (d) and Py8119 tumour volume (e) of the indicated mice±s.e.m. (n=5 Il1α−/− ND, n=4 Il1α−/− HFD, n=14 WT ND, n=24 WT HFD). (f,g) Data represent the average body weight (f) and tumour volume (g) of the indicated mice±s.e.m. ((e) n=5 Il1β−/− ND, n=5 Il1β−/− HFD, n=14 WT ND, n=24 WT HFD; f: n=1 Il1β−/− ND, n=2 Il1β−/− HFD). Only mice that had measurable tumours after 5 weeks are represented in g. Two-way ANOVA was used to determine significance. All tumour studies were repeated in a different cohort of animals.
Figure 1 The IL-1β/IL-1R1 axis promotes tumour growth in diet-induced obese mice. The indicated mice were given either a ND or HFD for 10 weeks, and then the indicated cells were implanted into the #4 mammary gland. See Supplementary Fig. 2b. (a–c) Mice were treated with anti-IL-1R1 antibody or control IgG once tumours were palpable (a,c) or with recombinant IL-1 receptor antagonist (rIL1RA) (b) starting the day of Py8119 cell transplant. Data represent the average tumour volume±s.e.m (a–b: n=5 HFD+IgG, n=5 HFD+anti-IL-1R1, n=5 HFD+anti-IL1RA n=14 ND, n=24 HFD; C: n=5 all groups). (d,e) Data represent the average body weight (d) and Py8119 tumour volume (e) of the indicated mice±s.e.m. (n=5 Il1α−/− ND, n=4 Il1α−/− HFD, n=14 WT ND, n=24 WT HFD). (f,g) Data represent the average body weight (f) and tumour volume (g) of the indicated mice±s.e.m. ((e) n=5 Il1β−/− ND, n=5 Il1β−/− HFD, n=14 WT ND, n=24 WT HFD; f: n=1 Il1β−/− ND, n=2 Il1β−/− HFD). Only mice that had measurable tumours after 5 weeks are represented in g. Two-way ANOVA was used to determine significance. All tumour studies were repeated in a different cohort of animals.CC BY · PubMed Central
Figure 2 NLRC4 inflammasome promotes tumour growth in diet-induced obese mice. (a–d) The indicated mice were treated as in Fig. 1. Data represent body weight (a) in Casp1/11−/− mice versus WT mice) or the average Py8119 tumour volume±s.e.m. (b–d; n=5 Casp1/11−/− ND, n=5 Casp1/11−/− HFD, n=5 Nlrp3−/− ND, n=4 Nlrp3−/− HFD, n=5 Nlrc4−/− ND, n=9 Nlrc4−/−- HFD n=14 WT ND, n=24 WT HFD). Two-way ANOVA was used to determine significance. (e) Py8119 tumour volumes 4 weeks after implantation from the indicated mice from a to d. Indicated P values are from a Student's t-test comparing individual group means. One-way ANOVA was performed across all groups: P<0.0001. (f) Average E0771 tumour volume±s.e.m. from the indicated mice (n=5 WT ND, n=5 WT HFD, n=5 Nlrc4−/− ND, n=9 Nlrc4−/− HFD). Two-way ANOVA was used to determine significance. All tumour studies were repeated in a different cohort of animals.
Figure 2 NLRC4 inflammasome promotes tumour growth in diet-induced obese mice. (a–d) The indicated mice were treated as in Fig. 1. Data represent body weight (a) in Casp1/11−/− mice versus WT mice) or the average Py8119 tumour volume±s.e.m. (b–d; n=5 Casp1/11−/− ND, n=5 Casp1/11−/− HFD, n=5 Nlrp3−/− ND, n=4 Nlrp3−/− HFD, n=5 Nlrc4−/− ND, n=9 Nlrc4−/−- HFD n=14 WT ND, n=24 WT HFD). Two-way ANOVA was used to determine significance. (e) Py8119 tumour volumes 4 weeks after implantation from the indicated mice from a to d. Indicated P values are from a Student's t-test comparing individual group means. One-way ANOVA was performed across all groups: P<0.0001. (f) Average E0771 tumour volume±s.e.m. from the indicated mice (n=5 WT ND, n=5 WT HFD, n=5 Nlrc4−/− ND, n=9 Nlrc4−/− HFD). Two-way ANOVA was used to determine significance. All tumour studies were repeated in a different cohort of animals.CC BY · PubMed Central
Figure 3 Obesity-induced NLRC4 inflammasome in tumour-infiltrating myeloid cells. (a) Data represent the number of tumour-infiltrating total (mφ), CD11c− or CD11c+ macrophages as a percentage of total cells counted±s.d. (n=5 ND; n=9 HFD). (b) mRNA expression (relative to peptidylprolyl isomerase A gene; Ppia) of the indicated genes in tumours from indicated mice (n=3)±s.d. (c) Western blot analysis for CASP1 (left panels) and CASP11 (right panels) in tumour-infiltrating CD11b+ and CD11b− cell populations. Cells were combined from four to five tumours from each group. (d) mRNA fold-change relative to the ND group, using Ppia as reference gene. Mean±s.d. in tumours from the indicated mice (n=3). (e,f) Nlrc4 mRNA expression in tumour-infiltrating CD11b+ and CD11b− cell populations from the indicated mice in the indicated tumour model, using Actin beta (Actb) as the reference gene. Cells were combined from four to five tumours from each group, and data are shown in triplicates. (g) Western blot for NLRC4-flag in tumour-infiltrating CD11b− and CD11b+ cell populations from DIO mice. (h) Data represent the average number of tumour-infiltrating CD45+ cells with CASP1 activation as a percentage of CD45+ cells±s.d. (n=5 WT ND, n=5 WT HFD, n=5 Nlrc4−/− ND, n=4 Nlrc4−/− HFD). For all panels, Student's t-test was used to determine significance. (i) NLRC4 activation from macrophages drives ODBP. Bone marrow macrophages from WT or Nlrc4−/− female mice were co-injected with Py8119 cells orthotopically into DIO Nlrc4−/− female mice. Tumour growth was monitored weekly (n=7, means±s.e.m.). Tumour study was repeated in a different cohort of animals. All other studies represent results from two to three repeats.
Figure 3 Obesity-induced NLRC4 inflammasome in tumour-infiltrating myeloid cells. (a) Data represent the number of tumour-infiltrating total (mφ), CD11c− or CD11c+ macrophages as a percentage of total cells counted±s.d. (n=5 ND; n=9 HFD). (b) mRNA expression (relative to peptidylprolyl isomerase A gene; Ppia) of the indicated genes in tumours from indicated mice (n=3)±s.d. (c) Western blot analysis for CASP1 (left panels) and CASP11 (right panels) in tumour-infiltrating CD11b+ and CD11b− cell populations. Cells were combined from four to five tumours from each group. (d) mRNA fold-change relative to the ND group, using Ppia as reference gene. Mean±s.d. in tumours from the indicated mice (n=3). (e,f) Nlrc4 mRNA expression in tumour-infiltrating CD11b+ and CD11b− cell populations from the indicated mice in the indicated tumour model, using Actin beta (Actb) as the reference gene. Cells were combined from four to five tumours from each group, and data are shown in triplicates. (g) Western blot for NLRC4-flag in tumour-infiltrating CD11b− and CD11b+ cell populations from DIO mice. (h) Data represent the average number of tumour-infiltrating CD45+ cells with CASP1 activation as a percentage of CD45+ cells±s.d. (n=5 WT ND, n=5 WT HFD, n=5 Nlrc4−/− ND, n=4 Nlrc4−/− HFD). For all panels, Student's t-test was used to determine significance. (i) NLRC4 activation from macrophages drives ODBP. Bone marrow macrophages from WT or Nlrc4−/− female mice were co-injected with Py8119 cells orthotopically into DIO Nlrc4−/− female mice. Tumour growth was monitored weekly (n=7, means±s.e.m.). Tumour study was repeated in a different cohort of animals. All other studies represent results from two to three repeats.CC BY · PubMed Central
Figure 4 NLRC4 inflammasome promotes angiogenesis in diet-induced obese mice. (a) Left panel: proteome profiler array for angiogenesis proteins using tumour lysates from ND and HFD mice (red boxes indicate the internal reference spots). Right panel: analysis of proteome profiler. Data represent the fold change compared with ND of the average mean pixel density±s.d. of select proteins. (b) Representative immunohistochemistry (IHC) staining for CD31 (brown colour, some indicated with white arrows) from the indicated Py8119 tumours, haematoxylin (blue) being used for background nuclear staining. An isotype-negative control staining is included (negative control). Scale bar, 200 μm. (c) Quantification of IHC staining in b. Data represent the average area of CD31-positive staining over total area±s.d. At least three fields per section and three tumours per group were used in the analysis. (d) Data represent the average number of CD31+ cells as a percentage of total cells counted by flow cytometry±s.d. in E0771 from tumours of the indicated mice (n=5 all groups). (e,f) Average Vegfa mRNA expression relative to Ppia in Py8119 tumours (e) and E0771 tumours (f) from the indicated mice±s.d. (n=3 for each group). All studies represent results from two to three repeats. For all panels, the group means were compared by Student's t-test to determine significance.
Figure 4 NLRC4 inflammasome promotes angiogenesis in diet-induced obese mice. (a) Left panel: proteome profiler array for angiogenesis proteins using tumour lysates from ND and HFD mice (red boxes indicate the internal reference spots). Right panel: analysis of proteome profiler. Data represent the fold change compared with ND of the average mean pixel density±s.d. of select proteins. (b) Representative immunohistochemistry (IHC) staining for CD31 (brown colour, some indicated with white arrows) from the indicated Py8119 tumours, haematoxylin (blue) being used for background nuclear staining. An isotype-negative control staining is included (negative control). Scale bar, 200 μm. (c) Quantification of IHC staining in b. Data represent the average area of CD31-positive staining over total area±s.d. At least three fields per section and three tumours per group were used in the analysis. (d) Data represent the average number of CD31+ cells as a percentage of total cells counted by flow cytometry±s.d. in E0771 from tumours of the indicated mice (n=5 all groups). (e,f) Average Vegfa mRNA expression relative to Ppia in Py8119 tumours (e) and E0771 tumours (f) from the indicated mice±s.d. (n=3 for each group). All studies represent results from two to three repeats. For all panels, the group means were compared by Student's t-test to determine significance.CC BY · PubMed Central
Figure 5 IL-1β-induced Vegfa expression in adipocytes. (a) Vegfa expression is increased in non-myeloid cells under obesity. CD11b+ and CD11b− cells were purified by magnetic beads in tumours from ND or DIO mice. Data represent the mean fold change compared with ND±s.d. Expression is relative to Actb (n=3 for each group). (b,c) Indicated cells were left untreated (cont), treated with 100 ng ml−1 rIL-1β or CM from non-treated or 100 ng ml−1 rIL-1β-treated primary BMDM. Data represent the average mRNA expression of Vegfa relative to Ppia as fold change compared with cont±s.d. (d) Adipocytes were treated as indicated with 100 ng ml−1 rIL-1β, 5 μM NFκB inhibitor (BMS345541) and 40 μM JNK inhibitor. Data represent the average mRNA expression of Vegfa relative to Ppia±s.d. (n=3 for all groups). (e) Primary mammary adipocytes were treated with 100 ng ml−1 rIL-1β for the indicated time, and the indicated proteins were separated by SDS–PAGE followed by immunoblotting with the indicated antibodies. All studies represent results from two to three repeats. For all panels, the group means were compared by Student's t-test to determine significance.
Figure 5 IL-1β-induced Vegfa expression in adipocytes. (a) Vegfa expression is increased in non-myeloid cells under obesity. CD11b+ and CD11b− cells were purified by magnetic beads in tumours from ND or DIO mice. Data represent the mean fold change compared with ND±s.d. Expression is relative to Actb (n=3 for each group). (b,c) Indicated cells were left untreated (cont), treated with 100 ng ml−1 rIL-1β or CM from non-treated or 100 ng ml−1 rIL-1β-treated primary BMDM. Data represent the average mRNA expression of Vegfa relative to Ppia as fold change compared with cont±s.d. (d) Adipocytes were treated as indicated with 100 ng ml−1 rIL-1β, 5 μM NFκB inhibitor (BMS345541) and 40 μM JNK inhibitor. Data represent the average mRNA expression of Vegfa relative to Ppia±s.d. (n=3 for all groups). (e) Primary mammary adipocytes were treated with 100 ng ml−1 rIL-1β for the indicated time, and the indicated proteins were separated by SDS–PAGE followed by immunoblotting with the indicated antibodies. All studies represent results from two to three repeats. For all panels, the group means were compared by Student's t-test to determine significance.CC BY · PubMed Central
Figure 6 Metformin inhibits tumour growth and angiogenesis in diet-induced obese mice. Mice were treated as in Fig. 1a; except after 9 weeks one group of ND and one group of HFD mice were fed with 0.5% metformin water. (a,b) Average Py8119 tumour volume (a) or body weight (b) ±s.e.m. (n=5 ND+Met, n=10 HFD+Met, n=14 ND, n=24 HFD). Two-way ANOVA was used to determine significance. (c) Representative IHC staining for CD31 from the indicated mice. Scale bar, 200 μm. (d) Quantification of IHC staining in c. Data represent the average area of CD31+ staining over total area±s.d. At least three fields per section and three tumours per group were used in the analysis. (e) Average mRNA expression of Vegfa±s.d. in tumours from the indicated mice (n=3). (f) Adipocytes were treated with 100 ng ml−1 rIL-1β and 500 μM metformin as indicated. Data represent the average Vegfa mRNA level relative to Ppia as a fold change compared with non-treated cells±s.d. (n=3). Tumour study was repeated in a different cohort of animals. All other studies represent results from two to three repeats. Group means were compared by Student's t-test to determine significance.
Figure 6 Metformin inhibits tumour growth and angiogenesis in diet-induced obese mice. Mice were treated as in Fig. 1a; except after 9 weeks one group of ND and one group of HFD mice were fed with 0.5% metformin water. (a,b) Average Py8119 tumour volume (a) or body weight (b) ±s.e.m. (n=5 ND+Met, n=10 HFD+Met, n=14 ND, n=24 HFD). Two-way ANOVA was used to determine significance. (c) Representative IHC staining for CD31 from the indicated mice. Scale bar, 200 μm. (d) Quantification of IHC staining in c. Data represent the average area of CD31+ staining over total area±s.d. At least three fields per section and three tumours per group were used in the analysis. (e) Average mRNA expression of Vegfa±s.d. in tumours from the indicated mice (n=3). (f) Adipocytes were treated with 100 ng ml−1 rIL-1β and 500 μM metformin as indicated. Data represent the average Vegfa mRNA level relative to Ppia as a fold change compared with non-treated cells±s.d. (n=3). Tumour study was repeated in a different cohort of animals. All other studies represent results from two to three repeats. Group means were compared by Student's t-test to determine significance.CC BY · PubMed Central
Figure 7 NLRC4 and CASP1 are associated with macrophage markers and poor outcome in human breast cancer. (a,b) NLRC4 mRNA is elevated in normal breast tissues from obese individuals (a) and is positively correlated with BMI (b). Number of cases indicated. Data from GSE33256 GEO data set. Statistical significance was determined by Welch's t-test (a) and linear regression and F test (b). (c) The mean NLRC4 and NLRP3 expression ±95% confidence interval (CI) in PAM50 subtypes of breast and normal breast tissue from TCGA-invasive breast cancer data set. Number of cases indicated. (d) CASP1 mRNA is elevated in obese breast cancer patients with luminal B and basal-like breast cancers. Data are presented as the mean±95% CI. Data are from GSE20194 GEO data set. Statistical significance was determined by Welch's t-test. (e) Correlation of NLRC4 expression (left two panels) or NLRP3 expression (right two panels) with overall survival in months within all human breast cancer patients (all) or within the ER+ breast cancers (ER+), analysed using KM-Plot meta-data set for invasive breast cancer. Statistical significance was determined by log-rank test comparing low versus high groups with number of cases indicated. (f) NLRC4 expression is positively correlated with macrophage markers including CD163 and common markers for myeloid cells such as CD68 and CD33, and is also correlated with IL1B expression in human breast cancer from TCGA (n=960 analysed from cBioPortal). Spearman and Pearson r values are indicated.
Figure 7 NLRC4 and CASP1 are associated with macrophage markers and poor outcome in human breast cancer. (a,b) NLRC4 mRNA is elevated in normal breast tissues from obese individuals (a) and is positively correlated with BMI (b). Number of cases indicated. Data from GSE33256 GEO data set. Statistical significance was determined by Welch's t-test (a) and linear regression and F test (b). (c) The mean NLRC4 and NLRP3 expression ±95% confidence interval (CI) in PAM50 subtypes of breast and normal breast tissue from TCGA-invasive breast cancer data set. Number of cases indicated. (d) CASP1 mRNA is elevated in obese breast cancer patients with luminal B and basal-like breast cancers. Data are presented as the mean±95% CI. Data are from GSE20194 GEO data set. Statistical significance was determined by Welch's t-test. (e) Correlation of NLRC4 expression (left two panels) or NLRP3 expression (right two panels) with overall survival in months within all human breast cancer patients (all) or within the ER+ breast cancers (ER+), analysed using KM-Plot meta-data set for invasive breast cancer. Statistical significance was determined by log-rank test comparing low versus high groups with number of cases indicated. (f) NLRC4 expression is positively correlated with macrophage markers including CD163 and common markers for myeloid cells such as CD68 and CD33, and is also correlated with IL1B expression in human breast cancer from TCGA (n=960 analysed from cBioPortal). Spearman and Pearson r values are indicated.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 58 references

Cited by

See all 247

Metadata

Authors
Kolb, R., Phan, L., Borcherding, N., Liu, Y., Yuan, F., Janowski, A. M., Xie, Q., Markan, K. R., Li, W., Potthoff, M. J., Fuentes-Mattei, E., Ellies, L. G., Knudson, C. M., Lee, M.-H., Yeung, S.-C. J., Cassel, S. L., Sutterwala, F. S., & Zhang, W.
Affiliations
  • University of Iowa (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Central South University (CN)
  • University of California San Diego (US)
Corresponding author
Zhang, Weizhou
Venue
Nature Communications
Published
2016-10-06
Volume
7
Issue
1
Pages
13007-13007
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2529393815
Cited by
239
References
58
Citations by year
2026: 9 · 2025: 18 · 2024: 17 · 2023: 34 · 2022: 27 · 2021: 37 · 2020: 39 · 2019: 24 · 2018: 17 · 2017: 14 · 2016: 2
FWCI
9.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (NIH T32, KG081048, NIH-R01, AI118719, CA158055)
  • University of Texas Health Science Center at San Antonio
  • Holden Comprehensive Cancer Center, University of Iowa (P30-CA086862)
  • National Cancer Institute (K99CA158055, CA203834, R00CA158055, R01CA200673, CA200673, L30 CA199587, R01CA203834, K22CA118182, P30CA086862)
  • National Institute of Allergy and Infectious Diseases (R56AI118719, T32AI007260, R01AI104706, T32AI007485, T32AI007517)
  • National Institute of Diabetes and Digestive and Kidney Diseases (K01DK111758)
  • National Institute on Minority Health and Health Disparities (L60 MD006355)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
obesity, breast cancer progression, NLRC4 inflammasome, tumor microenvironment, VEGF-A, angiogenesis, adipocytes, metformin
MeSH terms
Animals, Breast, Breast Neoplasms, Calcium-Binding Proteins, Female, Humans, Mammary Neoplasms, Experimental, Mice, Inbred C57BL, Neoplasm Transplantation, Obesity, Signal Transduction, Lymphocytes, Tumor-Infiltrating, Disease Progression, Myeloid Cells, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, CARD Signaling Adaptor Proteins, Interleukin-1beta, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.